Latest Breaking News On - ப்ரோக்ர்யாம் இல் புற்றுநோயியல் - Page 1 : comparemela.com

AVEO Oncology (Nasdaq: AVEO), a commercial and clinical development stage biopharmaceutical company, today announced the appointment of Kevin J. Cullen, M.D., to the Company’s Board of Directors. A widely recognized clinical oncologist with a specialty in head and neck cancer, Dr. Cullen is the Marlene and Stewart Greenebaum Distinguished Professor in Oncology and director of the Program in Oncology at the University of Maryland School of Medicine. He also serves as director of the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center. “Dr. Cullen, among the leading voices in cancer research and treatment, has made many important contributions to the evolving treatment of cancer, including head and neck cancers,” said Michael Bailey, president and chief executive officer of AVEO. “We are honored to welcome Dr. Cullen to the AVEO board of directors and look forward to his insights at a time where we embark on next steps in the clinic with our robus

United statesKevinj cullenMichael baileyNational cancer instituteDartmouth collegeGeorgetown universityProgram in oncologyUniversity of maryland school medicineEuropean unionPharmaceuticals incLombardi cancer center at georgetown universityStewart greenebaum comprehensive cancer centerCompany board of directorsNational cancer advisory boardNational institutes of healthDrug administration